S P Meditech Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 1.02 Cr
- Company Age 18 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
- Revenue Growth 80.87%
- Profit Growth 284.95%
- Ebitda 151.38%
- Net Worth 6.73%
- Total Assets 27.06%
About S P Meditech
S P Meditech Private Limited (SPMPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 09 June 2006 and has a history of 18 years and seven months. Its registered office is in Salem, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.02 Cr.
The company currently has active open charges totaling ₹1.00 Cr.
Myli Karuppan, Kalyani, and Ramaswamy Thirunavukarasu serve as directors at the Company.
Company Details
- Location
Salem, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U52311TZ2006PTC012839
- Company No.
012839
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jun 2006
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Who are the key members and board of directors at S P Meditech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramaswamy Thirunavukarasu  | Managing Director | 26-Mar-2018 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Myli Karuppan | Director | 26-Mar-2018 | Current |
| Kalyani | Director | 26-Mar-2018 | Current |
Financial Performance of S P Meditech.
S P Meditech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 80.87% increase. The company also saw a substantial improvement in profitability, with a 284.95% increase in profit. The company's net worth moved up by a moderate rise of 6.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S P Meditech?
In 2020, S P Meditech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2019 | Axis Bank Limited | ₹1.00 Cr | Open |
How Many Employees Work at S P Meditech?
S P Meditech has a workforce of 53 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S P Meditech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S P Meditech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
